Neoadjuvant therapy for breast cancer

Walter Mazzucco, Rosa Angela Filiberti, Giuliano Carrozzi, Pamela Minicozzi, Pamela Mancuso, Paolo Giorgi Rossi, Milena Sant, Silvia Iacovacci, Paolo Giorgi Rossi, Lucia Mangone, Giovanna Tagliabue, Rosario Tumino, Milena Sant

Risultato della ricerca: Article

2 Citazioni (Scopus)

Abstract

Objective: To evaluate the frequency of neoadjuvant therapy (NT) in women with stage I–III breast cancer in Italy and whether it is influenced by biological characteristics, screening history, and geographic area. Methods: Data from the High Resolution Study conducted in 7 Italian cancer registries were used; they are a representative sample of incident cancers in the study period (2009–2013). Included were 3546 women aged <85 years (groups <50, 50–69, 70–64, and 75+) with stage I–III breast cancer at diagnosis who underwent surgery. Women were classified as receiving NT if they received chemotherapy, target therapy, and/or hormone therapy before the first surgical treatment. Logistic models were built to test the association with biological and contextual variables. Results: Only 8.2% of women (290 cases) underwent NT; the treatment decreases with increasing age (14.5% in age <50 and 2.2% in age 75+), is more frequent in women with negative receptors (14.8%), HER2-positive (15.7%), and triple-negative (15.6%). The multivariable analysis showed the probability of receiving NT is higher in stage III (odds ratio [OR] 3.83; 95% confidence interval [CI] 2.83–5.18), luminal B (OR 1.87; 95% CI 1.27–2.76), triple-negatives (OR 1.88; 95% CI 1.15–3.08), and in symptomatic cancers (OR 1.98; 95% CI 1.13–3.48). Use of NT varied among geographic areas: Reggio Emilia had the highest rates (OR 2.29; 95% CI 1.37–3.82) while Palermo had the lowest (OR 0.41; 95% CI 0.24–0.68). Conclusions: The use of NT in Italy is limited and variable. There are no signs of greater use in hospitals with more advanced care.
Lingua originaleEnglish
pagine (da-a)488-493
Numero di pagine6
RivistaTumori
Volume105
Stato di pubblicazionePublished - 2019

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Entra nei temi di ricerca di 'Neoadjuvant therapy for breast cancer'. Insieme formano una fingerprint unica.

  • Cita questo

    Mazzucco, W., Filiberti, R. A., Carrozzi, G., Minicozzi, P., Mancuso, P., Giorgi Rossi, P., Sant, M., Iacovacci, S., Giorgi Rossi, P., Mangone, L., Tagliabue, G., Tumino, R., & Sant, M. (2019). Neoadjuvant therapy for breast cancer. Tumori, 105, 488-493.